The study's retrospective nature limited our ability to capture the reason patients were lost to follow-up.
Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis To the Editor: Urticaria is an allergic disease that can be classified into acute and chronic forms. Autoimmune responses are believed to contribute to the pathogenesis of chronic urticaria. 1 A vitamin D deficiency is associated with various autoimmune and allergic diseases, such as atopic dermatitis. 2 We attempted to meta-analyze current studies to elucidate the relationship between vitamin D deficiency and different types of urticaria in patients of different ages.
On November 30, 2017, we searched databases for studies comparing the prevalence of vitamin D deficiency or vitamin D levels between patients with urticaria and controls. Odds ratio (OR) and standardized mean difference (SMD) were calculated using a random effects model.
Fourteen studies with 1655 patients with urticaria were included for analysis. The pooled prevalence of vitamin D deficiency was significantly higher in patients with urticaria than in the control group (OR 4.456, 95% confidence interval [CI] 2.261-8.782; Fig 1) . Subgroup analysis revealed that the prevalence of vitamin D deficiency was significantly higher in patients with chronic urticaria than in the control group (OR 5.723, 95% CI 2.617-12.516), but a similar difference was not observed in patients with acute urticaria (OR 3.031, 95% CI 0.706-13.022).
Random effects pooling of the 11 studies providing vitamin D levels revealed that patients with urticaria had a significantly lower level of vitamin D than the control group (SMD À1.211, 95% CI À1.832 to À0.591; Fig 2) . Subgroup analysis indicated that the vitamin D level was significantly lower in patients with chronic urticaria than in the control group (SMD À1.067, 95% CI À1.865 to À0.268); vitamin D level was lower in patients with acute urticaria but the difference was not significant (SMD À1.009, 95% CI À2.314 to 0.296). The vitamin D level was significantly lower in adult patients with urticaria than the control group (SMD À1.741, 95% CI À3.472 to À0.010), but was not significantly lower in pediatric patients with urticaria than the control group (SMD À1.151, 95% CI À3.725 to 1.424).
The vitamin D pathway influences the allergic and autoimmune responses. 25-Hydroxyvitamin D3 is converted by mast cells into metabolites that repress IgE-mediated mast cell activation. 3 Vitamin D enhances T regulatory cells, which contributes to the suppression of proallergic and autoimmune responses. 4 ,5 1,25-Dihydroxyvitamin D has been reported to suppress T helper (T H ) 1 cytokine secretion, thereby inhibiting T H 1-mediated autoimmune diseases. 5 1,25-Dihydroxyvitamin D also suppresses T H 17 cells, an important trigger of autoimmune diseases. 5 This study was limited by the significant heterogeneity of the included studies. In addition, serum 25-hydroxyvitamin D levels are subject to many factors like comorbidity, sun exposure, and diet.
In summary, compared with the control group, the prevalence of 25-hydroxyvitamin D deficiency was significantly higher and the level of 25-hydroxyvitamin D was significantly lower in patients with chronic urticaria but not in those with acute urticaria. The significantly reduced level of 25-hydroxyvitamin D was observed in adult patients but not in pediatric patients. However, the association of vitamin D deficiency with urticaria does not imply causation. Further studies are required to explore the role of vitamin D supplementation in chronic solar urticaria. 3 Given these potential savings, understanding trends in generic and brand prescribing patterns is important, but little is known about these patterns among dermatologists in the Medicare population. A recent analysis of Medicare Part D prescription payments in 2013 reported that dermatologists prescribed the lowest proportion of brand name drugs among 30 specialties studied. 4 Although this study investigated general patterns of brand versus generic prescribing, to our knowledge, no studies have specifically investigated patterns and associated costs of generic and brand prescriptions among dermatologists.
We performed a cross-sectional analysis of population-based claims data from the 2015 Medicare Part D Prescriber Public Use and Summary files, which contain prescription brand name, generic name, claim count (including refills), and total Medicare spending organized by National Provider Identifier. All generic and branded medications prescribed by dermatologists were identified. Dermatologist-prescribed medications were divided into 7 classes: anti-infectives, antihistamines, biologics, immunomodulators, retinoids, topical steroids, and other. Medication classes included all routes of administration (oral, topical, and injection) unless otherwise stated. Drugs were designated as generic if the generic name variable matched the brand name variable in the data set. In instances in which syntax differed between brand and generic variables, for example, ''acetaminophen-codeine'' (brand variable) ¼ ''acetaminophen with codeine'' ( generic variable), we reclassified the medication as generic to avoid misclassification.
Statistical analysis was performed with Stata/MP 15.0 software (StataCorp, College Station, TX). Summary statistics were calculated for number of providers, total costs and claims per medication, total brand costs and claims, and proportion brand costs and claims. 
